Wells Fargo analyst Mohit Bansal lowered the firm’s price target on Bristol Myers (BMY) to $60 from $65 and keeps an Equal ...
Medicare beneficiaries using lower-priced negotiated drugs experienced out-of-pocket savings under the Medicare Drug Price ...
- Bristol Myers BMY-0.77% (BMY) and Novo Nordisk NVO+1.20% (NVO) trade at similar low P/E ratios but reflect divergent risks: ...
Millions of Americans who buy cheap drugs from Canada could soon lose access when a customs rule goes into effect later this ...
Ann Jackson, a Pittsford widow in the last stage of heart failure, wrote a letter to President Donald Trump asking him to ...
New customs requirements taking effect Oct. 22 could disrupt prescription deliveries for patients who rely on lower-cost ...
Bristol-Myers Squibb is reiterated as a buy, offering attractive valuation and a high 4.23% dividend yield. Click to read ...
Pfizer (NYSE:PFE) raised its revenue guidance in the second quarter of 2026, held its earnings guidance and announced another ...
A brief research report found that Medicare beneficiaries taking several commonly prescribed medications could see ...
Bristol-Myers Squibb is a Hold as replacing lost revenue from Eliquis and Opdivo presents a significant challenge. Click here ...
The number of medicine price concessions hit a new record high in September, the pharmacy negotiator has confirmed.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results